ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Total Liabilities
ExpreS2ion Biotech Holding AB
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Total Liabilities
kr28.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Liabilities
kr283.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Liabilities
kr168.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Liabilities
kr3.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
62%
|
CAGR 10-Years
31%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Liabilities
kr29.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
23%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Liabilities
kr608.1m
|
CAGR 3-Years
104%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Total Liabilities?
Total Liabilities
28.5m
SEK
Based on the financial report for Sep 30, 2025, ExpreS2ion Biotech Holding AB's Total Liabilities amounts to 28.5m SEK.
What is ExpreS2ion Biotech Holding AB's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-8%
Over the last year, the Total Liabilities growth was -19%. The average annual Total Liabilities growth rates for ExpreS2ion Biotech Holding AB have been 10% over the past three years , -8% over the past five years .
